Effects of treatment with premarin and clobetasol-premarin in vaginal disease after hematopoietic stem cell transplantation.

Comparison of the effects of treatment with premarine and clobetasol - premarin in vaginal involvement of GVHD (Graft-versus-host disease) after hematopoietic stem cell transplantation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160615028486N3

Enrollment

Registered

2022-07-27

Start date

2022-07-27

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Graft-versus-host disease (GVHD). Condition 2: Hematopoietic stem cell transplantation. Graft-versus-host disease Complications of stem cell transplant

Interventions

Intervention 1: Intervention group 1: Premarin cream is used once a day along with the mold for 6 weeks. Intervention 2: Intervention group 2: Clobetazol-premarin combined treatment is used every othe

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Female patients undergoing bone marrow transplantation Consent to participate in research

Exclusion criteria

Exclusion criteria: History of cervical cancer History of uterine,cervical,vaginal congenital anomaly Patient disagreement

Design outcomes

Primary

Measure	Time frame
Vaginal involvement of graft-versus-host disease. Timepoint: 1 year. Method of measurement: Gynecology examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansooreh Yaraghi

Tehran University of Medical Sciences

dr_m_yaraghi@yahoo.com+98 21 8490 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026